Alembic gets USFDA final approval for ANDA Docetaxel Injection

Sanofi reaffirms commitment to rare diseases in India

Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India

Agilent announces cell analysis workflow automation for immuno-oncology, virology, and vaccine development markets

New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator

EMA recommends refusal of the marketing authorization for Lagevrio

Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion.

Research underscores Beyfortus’ potential to prevent RSV disease in infants

The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile

Merck updates on Phase 3 MOVe-AHEAD trial evaluating Lagevrio

The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies

Mandaviya focuses on high value pharmaceuticals and high-end medical devices to reduce the import dependency

First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals

Merck and AstraZeneca present final results from Phase 3 PROpel Trial

Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival

USFDA accepts for priority review the sNDA for Merck’s Prevymis

FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients

Lupin receives EIR from USFDA for injectable facility in Nagpur

The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022